{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:28:51Z","timestamp":1790897331482,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dld.2026.01.211","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:11:10Z","timestamp":1769861470000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-4320","authenticated-orcid":false,"given":"Gael S.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Guarssifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Bennacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-932X","authenticated-orcid":false,"given":"Marie","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-5464","authenticated-orcid":false,"given":"Nicolas","family":"Williet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Dusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-187X","authenticated-orcid":false,"given":"Victoire","family":"Ruffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8765","authenticated-orcid":false,"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Nicolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.01.211_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.dld.2026.01.211_bib0002","doi-asserted-by":"crossref","first-page":"112","DOI":"10.14694\/EdBook_AM.2014.34.112","article-title":"Ampullary cancer: an overview","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.dld.2026.01.211_bib0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000230","article-title":"The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater","volume":"38","author":"Ang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2026.01.211_bib0004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-019-0415-8","article-title":"Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study","volume":"120","author":"Perkins","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.01.211_bib0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejso.2015.01.010","article-title":"Prognostic score for recurrence after Whipple\u2019s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort","volume":"41","author":"Colussi","year":"2015","journal-title":"Eur J Surg Oncol EJSO"},{"key":"10.1016\/j.dld.2026.01.211_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2024.04.027","article-title":"Ampullary tumors: french Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)","author":"Hautefeuille","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2026.01.211_bib0007","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.01.211_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000003177","article-title":"Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma: international Multicenter cohort study","volume":"272","author":"Moekotte","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2026.01.211_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49179-w","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2026.01.211_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133093","article-title":"Changing epidemiological trends of hepatobiliary carcinomas in Austria 2010\u20132018","volume":"14","author":"Hucke","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2026.01.211_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103988","article-title":"A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort","volume":"9","author":"Roth","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.01.211_bib0012","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/jso.25021","article-title":"Ampullary adenocarcinoma: defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease","volume":"117","author":"Stiles","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.dld.2026.01.211_bib0013","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1111\/ajco.12612","article-title":"Role of adjuvant chemotherapy in T2N0M0 periampullary cancers","volume":"13","author":"Ostwal","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.dld.2026.01.211_bib0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s11605-017-3624-6","article-title":"Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study","volume":"22","author":"Nassour","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2026.01.211_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2026.01.211_bib0016","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/bjs.11555","article-title":"Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study","volume":"107","author":"Moekotte","year":"2020","journal-title":"BJS Br J Surg"},{"key":"10.1016\/j.dld.2026.01.211_bib0017","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.01.211_bib0018","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.01.211_bib0019","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.01.211_bib0020","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.01.211_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105055","article-title":"Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative","volume":"10","author":"Taieb","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.01.211_bib0022","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with Fluorouracil plus folinic acid vs Gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.01.211_bib0023","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer","volume":"1","author":"Do-Youn","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.dld.2026.01.211_bib0024","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.01.211_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.01.211_bib0026","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.01.211_bib0027","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and Fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N Engl J Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600229X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600229X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:27:33Z","timestamp":1771504053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582600229X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S159086582600229X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.01.211","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.01.211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}